1 0

    FDA Summary Basis of Approval for NDA 218771 Almaject Teriparatide Injection

    FDA Summary Basis of Approval for NDA 218771 Almaject Teriparatide Injection

    $89.00 USD
    $89.00 USD
    Sale Sold out
    Original Request: A copy of the summary basis of approval, including any associated therapeutic equivalence determination, for NDA 218771 for Almaject, Inc.'s Teriparatide Injection, which was approved by FDA on or about June 4, 2024.
    Tags: Pharma, NDA, 2024
    • Status: Pending Fast-Track Request
    • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

    NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

    View full details